<DOC>
	<DOCNO>NCT00321711</DOCNO>
	<brief_summary>The purpose study evaluate effect Romiplostim ( AMG 531 ) incidence clinically significant thrombocytopenic event ( grade 3 4 and/or receipt platelet transfusion ) subject low intermediate risk Myelodysplastic Syndrome ( MDS ) receive hypomethylating agent . It hypothesize Romiplostim administration , appropriate dose schedule , result reduction incidence clinically significant thrombocytopenic event low intermediate risk MDS subject receive hypomethylating agent .</brief_summary>
	<brief_title>Determination Safe Effective Dose Romiplostim ( AMG 531 ) Subjects With Myelodysplastic Syndrome ( MDS ) Receiving Hypomethylating Agents</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis MDS bone marrow biopsy base World Health Organization ( WHO ) classification Low , Intermediate1 Intermediate2 risk category MDS use IPSS ( International Prognostic Scoring System ) Planned receive either azacytidine 75 mg/m2 subcutaneous administration day 7 day decitabine 20 mg/m2 intravenous administration day 5 day least 4 cycle Exclusion Criteria : Prior exposure &gt; 3 cycle hypomethylating agent Prior history leukemia aplastic anemia Prior history bone marrow transplantation Prior malignancy ( situ cervical cancer basal cell cancer skin ) unless treat curative intent without evidence disease Â³ 3 year randomization Active uncontrolled infection Unstable angina , congestive heart failure [ NYHA ( New York Heart Association ) &gt; class II ] , uncontrolled hypertension [ diastolic &gt; 100 mmHg ] , uncontrolled cardiac arrhythmia , recent ( within 1 year ) myocardial infarction History arterial thrombosis ( eg , stroke transient ischemic attack ) past year History venous thrombosis currently require anticoagulation therapy Received IL11 within 4 week screen Less 4 week since receipt therapeutic drug device FDA approve indication Have previously receive thrombopoietic growth factor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Refractory Cytopenias</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>